Nayid Jana

Program: Neurosciences

Current advisor: Tammie L.S. Benzinger, MD, PhD

Undergraduate university: University of Puerto Rico-Cayey, 2021

Enrollment year: 2022

Research summary
Amyloid Related Imaging Abnormalities in Patients Taking Lecanemab

Lecanemab is a new monoclonal antibody treatment for Alzheimer’s disease that was made available on 8/1/23. Many monoclonal antibodies, including lecanemab, can cause ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). The incidence and progression of ARIA depends on the treatment being used. It is often seen early in treatment, usually within the first 7 doses, and many patients are asymptomatic. However, serious life-threatening events such as intracerebral hemorrhages have been observed on patients being treated with this medication. ApoE4 genotype is the major risk factor for developing ARIA. Antithrombotic medications and age have been found to not increase the risk of ARIA.

We aim to see ARIA trends in the radiographic findings of patients on the lecanemab therapy. The key findings that will be reported are any cerebral hemorrhage >10 mm in greatest diameter, microhemorrhages, superficial siderosis, and vasogenic edema. This will provide a comprehensive workflow that radiologists can use to diagnose ARIA, characterize patient symptoms, and guide management.

Graduate publications
Paczynski M, Hofmann A, Posey Z, Gregersen M, Rudman M, Ellington D, Aldinger M, Musiek ES, Holtzman DM, Bateman RJ, Long JM, Ghoshal N, Carr DB, Dow A, Namazie-Kummer S, Jana N, Xiong C, Morris JC, Benzinger TLS, Schindler SE, Snider BJ. 2025 Lecanemab Treatment in a Specialty Memory Clinic. JAMA Neurol, 82(7):655-665. PMCID: PMC12070285

Doering S, McKay NS, Jana N, Dombrowski K, McCullough A, Millar PR, Hobbs DA, Agrawal R, Flores S, Llibre-Guerra JJ, Huey ED, Ances BM, Xiong C, Aschenbrenner AJ, Hassenstab J, Morris JC, Gordon BA, Benzinger TLS. 2024 Domain-specific cognitive impairment is differentially affected by Alzheimer disease tau pathologic burden and spread. Imaging Neurosci (Camb), 2():imag-2-00405. PMCID: PMC12176422